Asia Pacific Ulcerative Colitis Market Size, Share & Industry Trends Analysis Report By Molecule Type (Small Molecules and Biologics), By Disease Type, By Route of Administration, By Country and Growth Forecast, 2022-2028

The Asia Pacific Ulcerative Colitis Market is expected to witness market growth of 6.4% CAGR during the forecast period (2022-2028).

Fever, headache, rashes, low blood pressure, breathing difficulty, back discomfort, and stomach pain are all possible side effects of these genetically modified medications. Furthermore, these medicines may impair the body's ability to fight illness. The specific aetiology of ulcerative colitis is unknown, but hereditary causes, environmental changes, or a weaker immune system are all possibilities. Simple healthy practices like eating short meals throughout the day, staying hydrated throughout the day, avoiding greasy foods, and reducing high-fiber food intake can help to prevent ulcerative colitis.

The two key reasons driving the growth of the ulcerative colitis market are rising awareness and concerns about patients' health, as well as the advent of a significant number of pipeline compounds and government initiatives. Ulcerative colitis is a chronic condition that affects the large intestine, sometimes known as the colon. Ulcerative colitis is a disease in which the large intestine becomes inflamed, causing stomach pain, blood in the stool, and diarrhea. The market is growing because of the rising prevalence of ulcerative colitis around the world. Higher spending on research and development capacity to produce breakthrough therapies is also helping the market. The expansion of the ulcerative colitis therapy industry is also being fueled by increased efforts by governmental and non-governmental organizations to do biologics research.

The APAC region is witnessing a rising prevalence of Crohn's disease and ulcerative colitis in the region, increased prescription of biosimilars, and rising innovative medication approval. Men have a higher prevalence of Crohn's disease than women, according to a study published in NCBI. East Asia, which encompasses Japan, Korea, China, and other countries, has the highest prevalence of inflammatory bowel diseases. 
The pharmaceutical industry is finding it difficult to obtain raw materials and components from the Chinese market as a result of China's economic crisis. Even while some companies in China have reopened, crucial parts and raw materials are still in limited supply. As a result, different enterprises that import minor components and other elements to build finished products are seeing their margins and profitability suffer. In the short term, this aspect could put increasing pressure on drug prices. However, the COVID-19 pandemic has eventually presented a unique opportunity to investigate business from a different perspective. There is a chance that the principal producer and supplier of APIs, IVDs, and generic pharmaceuticals will transfer from China to India.

The China market dominated the Asia Pacific Ulcerative Colitis Market by Country 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $703.2 million by 2028. The Japan market is anticipated to grow at a CAGR of 5.8% during (2022-2028). Additionally, The India market is expected to showcase a CAGR of 7.1% during (2022-2028).

Based on Molecule Type, the market is segmented into Small Molecules and Biologics. Based on Disease Type, the market is segmented into Mild, Moderate, and Severe. Based on Route of Administration, the market is segmented into Oral and Injectables. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Abbott Laboratories, Ajinomoto Co., Inc., AstraZeneca PLC, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc., Sanofi S.A., InDex Pharmaceuticals Holding AB, and Eli Lilly And Company.

Scope of the Study

Market Segments Covered in the Report:

ByMolecule Type

• Small Molecules
• Biologics

By Disease Type

• Mild
• Moderate
• Severe

By Route of Administration

• Oral
• Injectables

By Country

• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific

Key Market Players

List of Companies Profiled in the Report:

• Abbott Laboratories
• Ajinomoto Co., Inc.
• AstraZeneca PLC
• GlaxoSmithKline PLC
• Johnson & Johnson
• Merck & Co., Inc.
• Pfizer, Inc.
• Sanofi S.A.
• InDex Pharmaceuticals Holding AB
• Eli Lilly And Company

Unique Offerings from the Publisher

• Exhaustive coverage
• The highest number of market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free